HC Wainwright Issues Negative Forecast for AVBP Earnings

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Investment analysts at HC Wainwright dropped their Q2 2026 earnings per share estimates for ArriVent BioPharma in a report released on Tuesday, May 12th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.95) per share for the quarter, down from their previous forecast of ($0.86). HC Wainwright has a “Buy” rating and a $44.00 price target on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($3.60) per share. HC Wainwright also issued estimates for ArriVent BioPharma’s Q3 2026 earnings at ($0.96) EPS, Q4 2026 earnings at ($0.99) EPS and FY2026 earnings at ($3.86) EPS.

Other equities research analysts have also recently issued research reports about the company. Citigroup dropped their target price on ArriVent BioPharma from $45.00 to $43.00 and set a “buy” rating on the stock in a report on Wednesday. B. Riley Financial boosted their target price on ArriVent BioPharma from $37.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, March 23rd. BTIG Research initiated coverage on ArriVent BioPharma in a report on Thursday, March 12th. They issued a “buy” rating and a $42.00 price target on the stock. Truist Financial raised ArriVent BioPharma to a “strong-buy” rating in a report on Monday, May 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ArriVent BioPharma in a report on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.78.

ArriVent BioPharma Price Performance

Shares of NASDAQ:AVBP opened at $28.93 on Thursday. ArriVent BioPharma has a 12 month low of $16.10 and a 12 month high of $32.14. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of -8.34 and a beta of 1.51. The stock’s 50 day moving average price is $26.37 and its 200 day moving average price is $23.29.

ArriVent BioPharma (NASDAQ:AVBP) last announced its earnings results on Monday, May 11th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.08).

Hedge Funds Weigh In On ArriVent BioPharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bessemer Group Inc. purchased a new position in ArriVent BioPharma during the 3rd quarter worth approximately $26,000. Mirae Asset Global Investments Co. Ltd. grew its position in ArriVent BioPharma by 27.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,006 shares of the company’s stock worth $40,000 after purchasing an additional 438 shares in the last quarter. Russell Investments Group Ltd. grew its position in ArriVent BioPharma by 9,747.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,068 shares of the company’s stock worth $38,000 after purchasing an additional 2,047 shares in the last quarter. BNP Paribas Financial Markets grew its position in ArriVent BioPharma by 31.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,571 shares of the company’s stock worth $56,000 after purchasing an additional 609 shares in the last quarter. Finally, Group One Trading LLC purchased a new position in ArriVent BioPharma during the 4th quarter worth approximately $57,000. 9.48% of the stock is currently owned by hedge funds and other institutional investors.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.